Lifordi Immunotherapeutics

Executive Summary

Lifordi Immunotherapeutics is a preclinical-stage biotechnology company based in Cambridge, MA, founded in 2021. The company is pioneering the use of antibody-drug conjugate (ADC) technology to treat autoimmune and inflammatory disorders, a novel application beyond oncology. Its lead program, LFD-200, is a targeted ADC for rheumatoid arthritis currently in a Phase 1 clinical trial. By leveraging a proprietary delivery platform, Lifordi aims to improve efficacy and safety compared to conventional biologics. The company operates in a competitive landscape but addresses a significant unmet need for safer, more effective autoimmune therapies. As a private, early-stage company with no disclosed funding or partnerships, its valuation is not publicly available. The upcoming Phase 1 data will be critical for demonstrating proof-of-concept and validating the ADC approach in autoimmune indications.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for LFD-200 in rheumatoid arthritis50% success
• H1 2027Initiation of Phase 1b/2 trial for LFD-200 in additional autoimmune indication30% success
• Q2 2026Announcement of strategic partnership or financing round25% success